Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
Outcomes are poor in patients with higher-risk myelodysplastic syndromes (HR MDS) and frontline treatment options are limited. This phase 1b study investigated safety and efficacy of venetoclax, a selective B-cell lymphoma 2 inhibitor, at the recommended phase 2 dose (RP2D; 400 mg for 14 days per 28...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 13 2025
|
| In: |
Blood
Year: 2025, Volume: 145, Issue: 11, Pages: 1126-1135 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood.2024025464 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2024025464
|
| Author Notes: | Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Uma Borate, Meagan A. Jacoby, Daniel Nowak, Maria R. Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, and Guillermo Garcia-Manero |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 193135832X | ||
| 003 | DE-627 | ||
| 005 | 20250721102925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250721s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2024025464 |2 doi | |
| 035 | |a (DE-627)193135832X | ||
| 035 | |a (DE-599)KXP193135832X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Garcia, Jacqueline S. |e VerfasserIn |0 (DE-588)1372007520 |0 (DE-627)1931360049 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes |c Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Uma Borate, Meagan A. Jacoby, Daniel Nowak, Maria R. Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, and Guillermo Garcia-Manero |
| 264 | 1 | |c March 13 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.07.2025 | ||
| 520 | |a Outcomes are poor in patients with higher-risk myelodysplastic syndromes (HR MDS) and frontline treatment options are limited. This phase 1b study investigated safety and efficacy of venetoclax, a selective B-cell lymphoma 2 inhibitor, at the recommended phase 2 dose (RP2D; 400 mg for 14 days per 28-day cycle), in combination with azacitidine (75 mg/m2 for 7 days per 28-day cycle) for treatment-naive HR MDS. Safety was the primary outcome, and complete remission (CR) rate was the primary efficacy outcome. Secondary outcomes included rates of modified overall response (mOR), hematologic improvement (HI), overall survival (OS), and time to next treatment (TTNT). As of May 2023, 107 patients received venetoclax and azacitidine combination at the RP2D. Best response of CR or marrow CR was observed in 29.9% and 50.5% (mOR, 80.4%), respectively. Median OS was 26.0 months, with 1- and 2-year survival estimates of 71.2% and 51.3%, respectively. Among 59 patients with baseline red blood cell and/or platelet transfusion-dependence, 24 (40.7%) achieved transfusion independence on study, including 11 (18.6%) in CR. Fifty-one (49.0%) of 104 evaluable patients achieved HI. Median TTNT excluding transplantation was 13.4 months. Adverse events reflected known safety profiles for venetoclax and azacitidine, including constipation (53.3%), nausea (49.5%), neutropenia (48.6%), thrombocytopenia (44.9%), febrile neutropenia (42.1%), and diarrhea (41.1%). Overall, venetoclax plus azacitidine at the RP2D was well tolerated and had favorable outcomes. A phase 3 study (NCT04401748) is ongoing to confirm survival benefit of this combination. This trial was registered at www.clinicaltrials.gov as #NCT02942290. | ||
| 700 | 1 | |a Platzbecker, Uwe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Odenike, Olatoyosi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fleming, Shaun |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fong, Chun Yew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borate, Uma |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jacoby, Meagan A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nowak, Daniel |d 1976- |e VerfasserIn |0 (DE-588)131932063 |0 (DE-627)51618041X |0 (DE-576)298844540 |4 aut | |
| 700 | 1 | |a Baer, Maria R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peterlin, Pierre |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chyla, Brenda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Huipei |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ku, Grace |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoffman, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Potluri, Jalaja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garcia-Manero, Guillermo |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d Washington, DC : American Society of Hematology, 1946 |g 145(2025), 11, Seite 1126-1135 |h Online-Ressource |w (DE-627)266886647 |w (DE-600)1468538-3 |w (DE-576)075961938 |x 1528-0020 |7 nnas |a Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes |
| 773 | 1 | 8 | |g volume:145 |g year:2025 |g number:11 |g pages:1126-1135 |g extent:10 |a Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes |
| 856 | 4 | 0 | |u https://doi.org/10.1182/blood.2024025464 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250721 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 131932063 |a Nowak, Daniel |m 131932063:Nowak, Daniel |d 60000 |d 61200 |d 60000 |e 60000PN131932063 |e 61200PN131932063 |e 60000PN131932063 |k 0/60000/ |k 1/60000/61200/ |k 0/60000/ |p 8 | ||
| 999 | |a KXP-PPN193135832X |e 4748238984 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Garcia","display":"Garcia, Jacqueline S.","given":"Jacqueline S.","role":"aut"},{"role":"aut","given":"Uwe","family":"Platzbecker","display":"Platzbecker, Uwe"},{"role":"aut","given":"Olatoyosi","family":"Odenike","display":"Odenike, Olatoyosi"},{"display":"Fleming, Shaun","family":"Fleming","role":"aut","given":"Shaun"},{"display":"Fong, Chun Yew","family":"Fong","given":"Chun Yew","role":"aut"},{"role":"aut","given":"Uma","display":"Borate, Uma","family":"Borate"},{"display":"Jacoby, Meagan A.","family":"Jacoby","role":"aut","given":"Meagan A."},{"display":"Nowak, Daniel","family":"Nowak","role":"aut","given":"Daniel"},{"role":"aut","given":"Maria R.","family":"Baer","display":"Baer, Maria R."},{"family":"Peterlin","display":"Peterlin, Pierre","role":"aut","given":"Pierre"},{"display":"Chyla, Brenda","family":"Chyla","given":"Brenda","role":"aut"},{"given":"Huipei","role":"aut","display":"Wang, Huipei","family":"Wang"},{"role":"aut","given":"Grace","display":"Ku, Grace","family":"Ku"},{"family":"Hoffman","display":"Hoffman, David","given":"David","role":"aut"},{"family":"Potluri","display":"Potluri, Jalaja","role":"aut","given":"Jalaja"},{"given":"Guillermo","role":"aut","display":"Garcia-Manero, Guillermo","family":"Garcia-Manero"}],"note":["Gesehen am 21.07.2025"],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"March 13 2025"}],"title":[{"title":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes","title_sort":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"noteIll":"Illustrationen","extent":"10 S."}],"name":{"displayForm":["Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Uma Borate, Meagan A. Jacoby, Daniel Nowak, Maria R. Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, and Guillermo Garcia-Manero"]},"recId":"193135832X","id":{"doi":["10.1182/blood.2024025464"],"eki":["193135832X"]},"relHost":[{"part":{"extent":"10","volume":"145","year":"2025","text":"145(2025), 11, Seite 1126-1135","pages":"1126-1135","issue":"11"},"origin":[{"dateIssuedDisp":"1946-","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","dateIssuedKey":"1946","publisher":"American Society of Hematology ; Saunders ; HighWire Press"}],"note":["Gesehen am 21.04.2023"],"titleAlt":[{"title":"Blood online"}],"title":[{"title":"Blood","subtitle":"journal of the American Society of Hematology","title_sort":"Blood"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"disp":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromesBlood","corporate":[{"display":"American Society of Hematology","role":"isb"}],"id":{"zdb":["1468538-3"],"eki":["266886647"],"issn":["1528-0020"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"266886647","pubHistory":["1.1946 -"]}]} | ||
| SRT | |a GARCIAJACQEFFICACYAN1320 | ||